Organization | Albert B. Sabin Vaccine Institute

Albert B. Sabin Vaccine Institute Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Washington D.C. United States (1993)

Organization Overview

First Clinical Trial

2006

NCT00713726

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Albert B. Sabin Vaccine Institute | The Albert B. Sabin Vaccine Institute

Active Ingredients

Drugs in Phase 4 Trials (2)

bnt162b2 (Comirnaty) (1 trial)

chadox1 (1 trial)

Drugs in Phase 3 Trials (2)

fentanyl (Innovar) (1 trial)

tramadol (Ultram) (1 trial)

Drugs in Phase 2 Trials (2)

cad3-marburg vaccine (2 trials)

cad3-zebov (2 trials)

Drugs in Phase 1 Trials (5)

aluminum hydroxide (Gaviscon) (2 trials)

gla-af (2 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

na-asp-2 (3 trials)

na-gst-1 (2 trials)

Drugs in Other Trials (2)

albendazole (Albenza) (1 trial)

ivermectin (stromectol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Agnosia (Phase 3)

Ancylostomiasis (Phase 1)

Hookworm Infections (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial APIs: 13